Fact sheet: UBS (L)E-Btech$

Fund information
Fund name
UBS (Lux) Equity - Biotech (USD) P Acc
Fund manager company
UBS AG
Fund type
No data available.
Fund managers
  • Scott Wilkinsince 19/06/2016
  • Nathalie Lötscher Petrussince 14/10/1996
Fund objective
Actively managed equity portfolio investing worldwide in biotech companies. Efficient means of exploiting the potential of biotech companies operating in research, product development, production or distribution. Specialised sector analysts seek out the most attractive stocks in the biotech sector worldwide. Investment decisions are based on a disciplined investment philosophy and fundamental research.
Benchmark
  • MSCI US Investable Market Biotechnology 10/40 Index
Investment style
None
Investment method
Shares
Quick stats
1 Year return
-17.2%
1 Year rank in sector
25/31
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
2.09%
Fund size
£1,062m (£1,506m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
207
Top in this sector
Fund name1 Year
Pictet Health2.9%
Fidelity Gbl Health Care2.6%
Variopartner SICAV MVGbMdtcF1%
BB Medtech-0.1%
Wellington GlHthcr LS-1.2%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

  • USA94.1%
    Switzerland2.6%
    UK2%
    Belgium0.9%
    International0.3%
  • Biotechnology/Medical100%
  • US Equities94.1%
    Swiss Equities2.6%
    UK Equities2%
    Belgian Equities0.9%
    International Equities0.3%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund7.1%-3.4%-4.1%-17.2%19%153.8%
Sector2.1%-4.2%-3.2%-11%24%107.6%
Rank within sector9 / 3215 / 3216 / 3225 / 3118 / 255 / 24
Quartile2nd2nd2nd4th3rd1st
Calendar performance
 YTD - 20162015201420132012
Fund-16.2%1.6%41.3%54.6%32.7%
Sector-10.6%7.2%28.1%41%16.7%
Rank within sector25 / 3126 / 294 / 267 / 242 / 24
Quartile4th4th1st2nd1st
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
-4.61
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
1.56
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.11
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
27.4
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
13.71
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
-0.13
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.87
Price movement
52 week high574.19
52 week low411
Current bid price-
Current offer price-
Current mid price475.72
Region
1USA94.07%
2Switzerland2.58%
3UK1.98%
4Belgium0.89%
5International0.27%
6Netherlands0.22%
Industry sector
1Biotechnology/Medical100%
Asset type
1US Equities94.07%
2Swiss Equities2.58%
3UK Equities1.98%
4Belgian Equities0.89%
5International Equities0.27%
6Dutch Equities0.22%
Individual holdings
1GILEAD SCIENCES INC9.99%
2AMGEN INC8.73%
3CELGENE CORP8.14%
4BIOGEN INC7%
5BIOMARIN PHARMACEUTICAL5.8%
6INCYTE CORP4.75%
7ABBVIE INC4.73%
8VERTEX PHARMACEUTICAL4.7%
9REGENERON PHARMACEUTICALS INC4.38%
Management
Fund manager group
UBS
Fund manager company
UBS AG
Fund type
No data available.
Fund objective
Actively managed equity portfolio investing worldwide in biotech companies. Efficient means of exploiting the potential of biotech companies operating in research, product development, production or distribution. Specialised sector analysts seek out the most attractive stocks in the biotech sector worldwide. Investment decisions are based on a disciplined investment philosophy and fundamental research.
Benchmark
  • MSCI US Investable Market Biotechnology 10/40 Index
Investment style
None
Investment method
Shares
Fund managers
NameSinceBiography
Scott Wilkin19/06/2016
Nathalie Lötscher Petrus14/10/1996
Compliance
Transparent for Austrian Tax, Transparent for Swiss Tax, Transparent for German Tax, UCITS IV Compliant
Domicile
No data available.
Fund for sale in
Austria, Switzerland, Chile, Cyprus, Germany, Denmark, Spain, Finland, France, United Kingdom, Greece, Italy, Republic Of Korea, Liechtenstein, Luxembourg, Netherlands, Norway, Offshore, Portugal, Singapore, Sweden, Taiwan - Province Of China
UBS (Lux) Equity - Biotech (USD) P Acc
Initial charge2%
Annual charge1.63%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.09%
Total expense ratio (TER)2.11%
Bid price-
Offer price-
Mid price475.72
CurrencyUSD
Price updated01/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeUB35
UBS (Lux) Equity - Biotech (USD) Q Acc
Initial charge2%
Annual charge0.82%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.07%
Total expense ratio (TER)1.08%
Bid price-
Offer price-
Mid price195.31
CurrencyUSD
Price updated01/12/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeF3OM
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.